IL315586A - Substituted tricyclic compounds as parp inhibitors and the use thereof - Google Patents
Substituted tricyclic compounds as parp inhibitors and the use thereofInfo
- Publication number
- IL315586A IL315586A IL315586A IL31558624A IL315586A IL 315586 A IL315586 A IL 315586A IL 315586 A IL315586 A IL 315586A IL 31558624 A IL31558624 A IL 31558624A IL 315586 A IL315586 A IL 315586A
- Authority
- IL
- Israel
- Prior art keywords
- methyl
- optionally substituted
- piperazin
- fluoro
- methylcarbamoyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210260944 | 2022-03-11 | ||
| CN202210448803 | 2022-04-24 | ||
| CN202211219599 | 2022-09-30 | ||
| CN202211505904 | 2022-11-28 | ||
| PCT/CN2023/077988 WO2023169226A1 (en) | 2022-03-11 | 2023-02-23 | Substituted tricyclic compounds as parp inhibitors and the use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315586A true IL315586A (en) | 2024-11-01 |
Family
ID=87937164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315586A IL315586A (en) | 2022-03-11 | 2023-02-23 | Substituted tricyclic compounds as parp inhibitors and the use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250215013A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4490161A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025508122A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240162104A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119013279A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023229992A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3253468A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315586A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024011086A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202400601A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023169226A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120081844A (zh) | 2022-01-21 | 2025-06-03 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| PT4497438T (pt) | 2022-04-28 | 2025-10-31 | Xinthera Inc C/O Gilead Sciences Inc | Inibidores tricíclicos da parp1 e suas utilizações |
| EP4524142A4 (en) * | 2022-05-07 | 2026-07-01 | Scibrunch Therapeutics Co Ltd | FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1 |
| AU2023378452A1 (en) * | 2022-11-10 | 2025-06-19 | Haihe Biopharma Co., Ltd. | Fused tricyclic parp1 inhibitor, preparation method therefor, and use thereof |
| JP2026507185A (ja) * | 2023-03-01 | 2026-02-27 | インパクト セラピューティクス (シャンハイ), インコーポレイテッド | Parp阻害剤としての置換窒素含有三環式化合物及びその使用 |
| CN120677162A (zh) * | 2023-06-13 | 2025-09-19 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
| TW202525808A (zh) * | 2023-09-13 | 2025-07-01 | 大陸商上海瑛派藥業有限公司 | 用作parp1抑制劑的化合物、其用途及包含其之組合物 |
| WO2026142998A1 (en) * | 2024-12-24 | 2026-07-02 | Gilead Sciences, Inc. | Crystalline forms of a parp1 inhibitor |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| CN101528704B (zh) * | 2006-09-01 | 2014-04-09 | 生华生物科技股份有限公司 | 丝氨酸-苏氨酸蛋白激酶和parp调节剂 |
| MX2009007053A (es) * | 2006-12-28 | 2009-07-09 | Abbott Lab | Inhibidores de poli (adp-ribosa) polimerasa. |
| EP2389379A1 (en) * | 2009-01-23 | 2011-11-30 | Takeda Pharmaceutical Company Limited | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors |
| US8541417B2 (en) * | 2009-07-30 | 2013-09-24 | Takeda Pharmaceutical Company Limited | Poly (ADP-ribose) polymerase (PARP) inhibitors |
| PT3312177T (pt) * | 2015-06-09 | 2021-05-17 | Onconic Therapeutics Inc | Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo |
| TW202309025A (zh) * | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
| AU2022334408A1 (en) * | 2021-08-27 | 2024-02-15 | Impact Therapeutics (Shanghai), Inc. | Substituted tricyclic compounds as parp inhibitors and use thereof |
| WO2023122140A1 (en) * | 2021-12-22 | 2023-06-29 | Synnovation Therapeutics, Inc. | Parp1 inhibitors |
| US20250221987A1 (en) * | 2022-01-13 | 2025-07-10 | Acerand Therapeutics (Hong Kong) Limited | Piperazino ring-containing derivative, pharmaceutically acceptable salt thereof, preparation method therefor, and application thereof |
| PT4497438T (pt) * | 2022-04-28 | 2025-10-31 | Xinthera Inc C/O Gilead Sciences Inc | Inibidores tricíclicos da parp1 e suas utilizações |
| EP4524142A4 (en) * | 2022-05-07 | 2026-07-01 | Scibrunch Therapeutics Co Ltd | FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1 |
| CN115232129B (zh) * | 2022-08-18 | 2023-12-01 | 上海闻耐医药科技有限公司 | 一种parp1选择性抑制剂及其制备方法和用途 |
| AU2023378452A1 (en) * | 2022-11-10 | 2025-06-19 | Haihe Biopharma Co., Ltd. | Fused tricyclic parp1 inhibitor, preparation method therefor, and use thereof |
-
2023
- 2023-02-23 AU AU2023229992A patent/AU2023229992A1/en active Pending
- 2023-02-23 US US18/846,265 patent/US20250215013A1/en active Pending
- 2023-02-23 JP JP2024553758A patent/JP2025508122A/ja active Pending
- 2023-02-23 IL IL315586A patent/IL315586A/en unknown
- 2023-02-23 WO PCT/CN2023/077988 patent/WO2023169226A1/en not_active Ceased
- 2023-02-23 CA CA3253468A patent/CA3253468A1/en active Pending
- 2023-02-23 KR KR1020247033867A patent/KR20240162104A/ko active Pending
- 2023-02-23 CN CN202380026468.5A patent/CN119013279A/zh active Pending
- 2023-02-23 EP EP23765804.2A patent/EP4490161A4/en active Pending
- 2023-03-01 TW TW112107292A patent/TW202400601A/zh unknown
-
2024
- 2024-09-10 MX MX2024011086A patent/MX2024011086A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024011086A (es) | 2024-12-06 |
| JP2025508122A (ja) | 2025-03-21 |
| EP4490161A1 (en) | 2025-01-15 |
| WO2023169226A1 (en) | 2023-09-14 |
| KR20240162104A (ko) | 2024-11-14 |
| CN119013279A (zh) | 2024-11-22 |
| EP4490161A4 (en) | 2026-03-11 |
| CA3253468A1 (en) | 2023-09-14 |
| US20250215013A1 (en) | 2025-07-03 |
| AU2023229992A1 (en) | 2024-10-10 |
| TW202400601A (zh) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109906227B (zh) | 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物 | |
| IL311024A (en) | Substituted tricyclic compounds as parp inhibitors and use thereof | |
| JP2025508122A (ja) | Parp阻害剤としての置換三環式化合物およびその使用 | |
| CN104520290B (zh) | 酰氨基螺环酰胺和磺酰胺衍生物 | |
| CN112142744A (zh) | 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用 | |
| TW200900404A (en) | Pyrazolopyrimidine analogs and their use as mTOR kinase and PI3 kinase inhibitors | |
| WO2017092635A1 (zh) | 一种蛋白激酶抑制剂及其制备方法和医药用途 | |
| TW202332438A (zh) | Parp1抑制劑 | |
| CN104507936A (zh) | 吡啶基和嘧啶基亚砜和砜衍生物 | |
| CN110914277B (zh) | 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用 | |
| JP2015508784A (ja) | アミド−ベンジルスルホン及びスルホキシド誘導体 | |
| CN110312717B (zh) | 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用 | |
| US20240208969A1 (en) | Substituted fused bicyclic compounds as parp inhibitors and the use thereof | |
| CN107848971B (zh) | 杂环化合物 | |
| CN121925419A (zh) | 一种吡啶-2(1h)-酮类prmt5-mta抑制剂、其药物组合物及其应用 | |
| HK40115331A (en) | Substituted tricyclic compounds as parp inhibitors and the use thereof | |
| WO2024179547A1 (en) | Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof | |
| HK40104162A (en) | Substituted tricyclic compounds as parp inhibitors and use thereof | |
| CN112047877A (zh) | 新型酰胺类化合物及其用途 | |
| CN119371425A (zh) | 含氮杂环类化合物及其制备方法和医药用途 |